Patents by Inventor Esther CLEARY

Esther CLEARY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR7/8 antagonists and uses thereof
    Patent number: 11512069
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: November 29, 2022
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210300940
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: July 29, 2019
    Publication date: September 30, 2021
    Applicant: Merck Patent GmbH
    Inventors: Brian Sherer, Ruoxi Lan, Nadia Brugger, Xiaoling Chen, Momar Toure, Esther Cleary, Lizbeth Celeste Deselm, Yanping Wang
  • TLR7/8 antagonists and uses thereof
    Patent number: 10947214
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210002255
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. SHERER, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210002256
    Abstract: A compound of Formula I or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20180037570
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Application
    Filed: August 7, 2017
    Publication date: February 8, 2018
    Inventors: Brian A. SHERER, Xiaoling CHEN, Esther CLEARY, Nadia BRUGGER